<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thirty adults with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> at high-risk for relapse were treated on a phase I-II study of high-dose thiotepa, <z:chebi fb="0" ids="28901">busulfan</z:chebi> (BU) and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY) as the preparative regimen for allogeneic marrow transplantation </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="4031">Cyclosporine</z:chebi> and <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> or anti-CD5 ricin A chain immunoconjugate were used as <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> prophylaxis </plain></SENT>
<SENT sid="2" pm="."><plain>Filgrastim was given from day 1 to enhance engraftment </plain></SENT>
<SENT sid="3" pm="."><plain>Median follow-up time is 16 months (range 9-29 months) </plain></SENT>
<SENT sid="4" pm="."><plain>Grades III-IV regimen-related toxicity occurred in 5 (26%) of 19 patients treated with thiotepa 250 mg/m2 x 3, BU 1 mg/kg x 12 and CY 60 mg/kg x 2 and this was considered the maximal tolerated dose-schedule </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0010280'>Stomatitis</z:hpo> and hepatoxicity were dose-limiting </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients engrafted and had complete donor chimerism </plain></SENT>
<SENT sid="7" pm="."><plain>The actuarial rate of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> was 71% (95% CI 62-80%) </plain></SENT>
<SENT sid="8" pm="."><plain>The relapse rate at 1 year was 38% (95% CI 25-50%) and the actuarial survival at 1 year was 30% (95% CI 22-38%) </plain></SENT>
<SENT sid="9" pm="."><plain>The combination of thiotepa, BU and CY is tolerable as a preparative regimen for allogeneic marrow transplantation </plain></SENT>
</text></document>